Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

1.

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.

Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, Revicki DA, Buchanan RW.

BMJ. 2002 Aug 3;325(7358):243.

PMID:
12153919
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.

Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, Revicki D, Buchanan RW.

Arch Gen Psychiatry. 2002 Nov;59(11):1021-6.

PMID:
12418935
[PubMed - indexed for MEDLINE]
3.

Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.

Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA.

J Clin Psychiatry. 2002 Oct;63(10):920-30.

PMID:
12416602
[PubMed - indexed for MEDLINE]
4.

Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine.

Fuller MA, Shermock KM, Secic M, Grogg AL.

Pharmacotherapy. 2003 Aug;23(8):1037-43.

PMID:
12921249
[PubMed - indexed for MEDLINE]
5.

Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders.

Gianfrancesco F, Grogg A, Mahmoud R, Wang RH, Meletiche D.

Clin Ther. 2003 Apr;25(4):1150-71.

PMID:
12809963
[PubMed - indexed for MEDLINE]
6.

Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States.

Feldman PD, Hay LK, Deberdt W, Kennedy JS, Hutchins DS, Hay DP, Hardy TA, Hoffmann VP, Hornbuckle K, Breier A.

J Am Med Dir Assoc. 2004 Jan-Feb;5(1):38-46.

PMID:
14706127
[PubMed - indexed for MEDLINE]
7.

[Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].

Rubio G, Gómez-de-la-Cámara A, Ledesma F, Burón JA, Rodríguez-Morales A, Martínez-Junquera G; Grupo Español para el Estudio de la Diabetes en Pacientes Esquizofrénicos.

Med Clin (Barc). 2006 Apr 1;126(12):441-4. Spanish.

PMID:
16620729
[PubMed - indexed for MEDLINE]
8.

The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis.

Caro JJ, Ward A, Levinton C, Robinson K.

J Clin Psychiatry. 2002 Dec;63(12):1135-9.

PMID:
12523873
[PubMed - indexed for MEDLINE]
9.

Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.

Lambert BL, Chou CH, Chang KY, Tafesse E, Carson W.

Pharmacoepidemiol Drug Saf. 2005 Jun;14(6):417-25.

PMID:
15786516
[PubMed - indexed for MEDLINE]
10.

The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.

Ritchie CW, Chiu E, Harrigan S, Hall K, Hassett A, Macfarlane S, Mastwyk M, O'Connor DW, Opie J, Ames D.

Int J Geriatr Psychiatry. 2003 May;18(5):432-40.

PMID:
12766921
[PubMed - indexed for MEDLINE]
11.

Weight gain and new onset diabetes associated with olanzapine and risperidone.

Farwell WR, Stump TE, Wang J, Tafesse E, L'Italien G, Tierney WM.

J Gen Intern Med. 2004 Dec;19(12):1200-5.

PMID:
15610330
[PubMed - indexed for MEDLINE]
Free PMC Article
12.
13.

Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: sensitivity to study design.

Gianfrancesco F, Pesa J, Wang RH, Nasrallah H.

Am J Health Syst Pharm. 2006 Mar 1;63(5):431-41.

PMID:
16484517
[PubMed - indexed for MEDLINE]
14.

Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.

Bobes J, Rejas J, Garcia-Garcia M, Rico-Villademoros F, García-Portilla MP, Fernández I, Hernández G; EIRE Study Group.

Schizophr Res. 2003 Jul 1;62(1-2):77-88.

PMID:
12765747
[PubMed - indexed for MEDLINE]
15.

Glucose intolerance with atypical antipsychotics.

Hedenmalm K, Hägg S, Ståhl M, Mortimer O, Spigset O.

Drug Saf. 2002;25(15):1107-16.

PMID:
12452735
[PubMed - indexed for MEDLINE]
16.

Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia.

Lambert BL, Cunningham FE, Miller DR, Dalack GW, Hur K.

Am J Epidemiol. 2006 Oct 1;164(7):672-81. Epub 2006 Aug 30.

PMID:
16943266
[PubMed - indexed for MEDLINE]
Free Article
17.

Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a population-based comparison of risperidone and olanzapine.

Moisan J, Grégoire JP, Gaudet M, Cooper D.

Pharmacoepidemiol Drug Saf. 2005 Jun;14(6):427-36.

PMID:
15786513
[PubMed - indexed for MEDLINE]
18.

Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study.

Guo JJ, Keck PE Jr, Corey-Lisle PK, Li H, Jiang D, Jang R, L'Italien GJ.

J Clin Psychiatry. 2006 Jul;67(7):1055-61.

PMID:
16889448
[PubMed - indexed for MEDLINE]
19.

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.

Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R.

Am J Psychiatry. 2002 Apr;159(4):561-6.

PMID:
11925293
[PubMed - indexed for MEDLINE]
20.

Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients.

Citrome L, Jaffe A, Levine J, Allingham B, Robinson J.

Psychiatr Serv. 2004 Sep;55(9):1006-13.

PMID:
15345760
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk